Cited by 11Lung Cancer Diagnosis and TreatmentLung Cancer Research StudiesMetastasis and carcinoma case studies

Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma

Suaiti, Lubna, Sullivan, Travis B., Rieger-Christ, Kimberly M., Servais, Elliot L., Suzuki, Kei, Burks, Eric J.·2023·Clinical Lung Cancer

Abstract

Background Lymphovascular invasion (LVI) is an adverse prognostic feature in resected stage I non-small cell lung cancer (NSCLC); however, it is unclear if the prognostic significance applies to both lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC).Materials and methods A retrospective review of H&E-stained slides from surgically resected AJCC 8 th ed. stage IA2-IB LUAD (n = 344) and LUSC (n = 102) from two institutions was performed. LVI was defined as either lymphatic (LI) or vascular (VI) invasion. Outcomes were assessed by 5-year recurrence-free survival (RFS) estimates using the Kaplan-Meier method.Results The cohorts of LUAD and LUSC showed no significant differences in 5-year RFS (81% each), stage, age, race, or surgical procedure. The presence of LVI, VI, and LI was predictive of 5-year RFS for LUAD (LVI + 71% vs. LVI - 92%, P < 0.001; VI + 64% vs. VI - 90%, P < 0.001; LI + 75% vs. LI - 84%, P = 0.030) but not LUSC (LVI + 84% vs. LVI - 79%, P = 0.740; VI + 83% vs. VI- 80%, P = 0.852; LI + 84% vs. LI - 81%, P = 0.757). Among LUAD with LVI, VI was a stronger predictor of 5-year RFS than the remaining subset of VI-LI + tumors (64% vs. 87%, P = 004). Subset analysis of LI among LUAD stratified by VI showed no significant prognostic advantage to adding LI for risk stratification (VI-LI + 87% vs. VI-LI - 92%, P = 0.347 & VI+LI + 62% vs. VI + LI- 66%, P = 0.422). VI was present in 36% of LUAD.Conclusion Vascular invasion is a strong predictor of recurrence in stage IA2-IB LUAD but not in LUSC. Adjuvant therapy trials should be directed at this subgroup.

Integrity signals

Registry

Crossref · 10.1016/j.cllc.2022.12.006

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In the LUAD high-risk case, the FSM model highlighted the aggressive solid tumor histologic pattern and the focus of vascular invasion [35], [36] associated with an unfavorable prognosis.

    “In the LUAD high-risk case, the FSM model highlighted the aggressive solid tumor histologic pattern and the focus of vascular invasion [35], [36] associated with an unfavorable prognosis.”

Cites

Flagged first, then by citations

1 of the 38 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Suaiti, L., Sullivan, T. B., Rieger-Christ, K. M., Servais, E. L., Suzuki, K., & Burks, E. J.
Affiliations
  • Boston University (US)
  • Lahey Hospital and Medical Center (US)
Corresponding author
Burks, Eric J.
Venue
Clinical Lung Cancer
Publisher
Elsevier BV
Published
2023-05
Volume
24
Issue
3
Pages
e126-e133
ISSN
1525-7304 (ISSN-L)
OpenAlex
W4313201705
Cited by
11
References
38
Citations by year
2026: 2 · 2025: 3 · 2024: 4 · 2023: 2
FWCI
1.45
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Lung Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Metastasis and carcinoma case studies
Keywords
vascular invasion, lymphovascular invasion, lung adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, stage I lung cancer, recurrence-free survival, prognostic factors, lymphatic invasion, adjuvant therapy, risk stratification, surgical resection, molecular subtypes, EGFR, KRAS, anaplastic lymphoma kinase, BRAF, IDH1, IDH2
MeSH terms
Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Humans, Lung Neoplasms, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Prognosis, Retrospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review